pubmed.ncbi.nlm.nih.gov

Effect of dietary Fatty acids on human lipoprotein metabolism: a comprehensive update - PubMed

  • ️Thu Jan 01 2015

Review

Effect of dietary Fatty acids on human lipoprotein metabolism: a comprehensive update

Esther M M Ooi et al. Nutrients. 2015.

Abstract

Dyslipidemia is a major risk factor for cardiovascular disease (CVD). Dietary fatty-acid composition regulates lipids and lipoprotein metabolism and may confer CVD benefit. This review updates understanding of the effect of dietary fatty-acids on human lipoprotein metabolism. In elderly participants with hyperlipidemia, high n-3 polyunsaturated fatty-acids (PUFA) consumption diminished hepatic triglyceride-rich lipoprotein (TRL) secretion and enhanced TRL to low-density lipoprotein (LDL) conversion. n-3 PUFA also decreased TRL-apoB-48 concentration by decreasing TRL-apoB-48 secretion. High n-6 PUFA intake decreased very low-density lipoprotein (VLDL) cholesterol and triglyceride concentrations by up-regulating VLDL lipolysis and uptake. In a study of healthy subjects, the intake of saturated fatty-acids with increased palmitic acid at the sn-2 position was associated with decreased postprandial lipemia. Low medium-chain triglyceride may not appreciably alter TRL metabolism. Replacing carbohydrate with monounsaturated fatty-acids increased TRL catabolism. Trans-fatty-acid decreased LDL and enhanced high-density lipoprotein catabolism. Interactions between APOE genotype and n-3 PUFA in regulating lipid responses were also described. The major advances in understanding the effect of dietary fatty-acids on lipoprotein metabolism has centered on n-3 PUFA. This knowledge emphasizes the importance of regulating lipoprotein metabolism as a mode to improve plasma lipids and potentially CVD risk. Additional studies are required to better characterize the cardiometabolic effects of other dietary fatty-acids.

Keywords: cardiovascular disease; dietary fatty acids; dyslipidemia; lipoprotein metabolism.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Millen B.E., Wolongevicz D.M., de Jesus J.M., Nonas C.A., Lichtenstein A.H. 2013 American Heart Association/American College of Cardiology Guideline on lifestyle management to reduce cardiovascular risk: Practice opportunities for registered dietitian nutritionists. J. Acad. Nutr. Diet. 2014;114:1723–1729. doi: 10.1016/j.jand.2014.07.037. - DOI - PubMed
    1. Harris W.S. Are n-3 fatty acids still cardioprotective? Curr. Opin. Clin. Nutr. Metab Care. 2013;16:141–149. doi: 10.1097/MCO.0b013e32835bf380. - DOI - PubMed
    1. Mori T.A. Dietary n-3 PUFA and CVD: A review of the evidence. Proc. Nutr. Soc. 2014;73:57–64. doi: 10.1017/S0029665113003583. - DOI - PubMed
    1. Mozaffarian D., Wu J.H. Omega-3 fatty acids and cardiovascular disease: Effects on risk factors, molecular pathways, and clinical events. J. Am. Coll. Cardiol. 2011;58:2047–2067. doi: 10.1016/j.jacc.2011.06.063. - DOI - PubMed
    1. Caviglia J.M., Gayet C., Ota T., Hernandez-Ono A., Conlon D.M., Jiang H., Fisher E.A., Ginsberg H.N. Different fatty acids inhibit apoB100 secretion by different pathways: Unique roles for ER stress, ceramide, and autophagy. J. Lipid Res. 2011;52:1636–1651. doi: 10.1194/jlr.M016931. - DOI - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources